Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Hyperthermia 2Breast Neoplasms 2Uveal Melanoma 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Retinoblastoma 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 13pembrolizumab 9Specimen Handling 9enfortumab vedotin 8Cisplatin 8Magnetic Resonance Spectroscopy 7avelumab 5Carboplatin 5vinflunine 4Nivolumab 4atezolizumab 3Immunoglobulin G 3Disulfides 3Biopsy 3eribulin 2cabozantinib 2Standard of Care 2Ramucirumab 2Radiotherapy 2Platinum 2Nephroureterectomy 2Ipilimumab 2Doxorubicin 2Docetaxel 2CTLA-4 Antigen 2Bortezomib 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1tremelimumab 1tocilizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ureteral Neoplasms × Hyperthermia, Induced × Clear all
NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Mayo Clinic

Phase 4 Recruiting
75 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡